A multicenter, observational study for reactivation of hepatitis B virus by means of serial HBV-DNA monitoring during and just after systemic chemotherapy containing rituximab plus steroid for malignant lymphoma (C-SHOT 0802)

Trial Profile

A multicenter, observational study for reactivation of hepatitis B virus by means of serial HBV-DNA monitoring during and just after systemic chemotherapy containing rituximab plus steroid for malignant lymphoma (C-SHOT 0802)

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Pirarubicin; Prednisolone; Procarbazine; Vincristine
  • Indications B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Oct 2017 Results of retrospective analysis assessing clinical significance of HBsAg assay to diagnosing HBV reactivation by using data from this study presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 12 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top